Skip to main content
. Author manuscript; available in PMC: 2017 Mar 17.
Published in final edited form as: Circulation. 2011 Jul 5;124(3):335–345. doi: 10.1161/CIRCULATIONAHA.110.985150

Figure 2.

Figure 2

In study 2, there was no significant difference in the change in low-density lipoprotein (LDL) levels between patients who received atorvastatin (n=21) and those who received placebo (n=21; P=0.704; A). However, flow-mediated dilation (FMD) was improved in the atorvastatin-treated group compared with placebo (B). There was no significant difference (P=0.774) in the changes in endothelium-independent dilatation of the brachial artery in response to nitroglycerine (NTG) between the 2 groups (C). P values were derived by using 2-way ANOVA for repeated measures with time-by-treatment interaction on the log-transformed values. Values expressed as median (25th to 75th percentile).